Adverse events following vaccine or placebo injection in an efficacy trial of an outer membrane vesicle vaccine against group B meningococcal disease in Norwegian secondary schools 1988-1991.
Aavitsland
P
P
Department of Infectious Disease Control, National Institute of Publich Health, Oslo.
Bjune
G
G
Aasen
S
S
Halvorsen
S
S
D000293:Adolescent; D016907:Adverse Drug Reaction Reporting Systems / Q000592:standards; D016667:Bacterial Capsules; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D001428:Bacterial Vaccines / Q000009:adverse effects* / Q000276:immunology; D004311:Double-Blind Method; D006801:Humans; D022401:Meningococcal Vaccines; D009422:Nervous System Diseases / Q000139:chemically induced / Q000453:epidemiology; D009664:Norway / Q000453:epidemiology; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D012574:Schools
D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D022401:Meningococcal Vaccines; D011135:Polysaccharides, Bacterial; C039455:capsular polysaccharide, meningococcal group B